** Shares of Switzerland-based drug developer Pharvaris PHVS.O fall 8.9% to $21.06
** PHVS announces offering of 8.25 million shares and pre-funded warrants to purchase 500,000 ordinary shares for gross proceeds of $175 million
** Effective price of $20 represents a 13.5% discount to stock's last close
** PHVS had initially planned on selling $150 million of shares in the stock offering
** Morgan Stanley, Leerink Partners, Cantor, Oppenheimer, and Van Lanschot Kempen were the joint book-running managers
** 10 of 11 brokerages rate the stock "buy" or higher and 1 "sell"; median PT $30 - data compiled by LSEG
** As of last close, PHVS stock up 20.6% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.